Back

Transthyretin amyloid cardiomyopathy (ATTR-CM): a potential role for cardiopulmonary exercise testing

19 May 2025 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Treatment considerations in amyloidosis Exercise Testing HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rita Amador

Hospital Santa Cruz, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Systematic screening for transthyretic cardiac amyloidosis in patients undergoing TAVI: results from a greek-cypriot registry
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients
Doctor J. Fernandes Pedro (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Exploring tafamidis outcomes across varying disease severities in ATTR-CM
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Tafamidis and patient-reported outcomes in ATTR cardiomyopathy
Mr D. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Prevalence and clinical implications of conduction system disease in patients with cardiac transthyretin amyloidosis
Doctor L. Schlender (Frankfurt, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment considerations in amyloidosis

The Event

Event poster

Heart Failure 2025

19 May 2025 12:00 CET
You may be interested in
thumbnail
Congress Presentation
The role of CPET for the assessment of patients with transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy
thumbnail
Congress Presentation
Poor cardiopulmonary exercise testing correlates with high quantitative SPECT/CT uptake

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources